Researchers at the University of Utah were able to get mice to walk again after suffering from MS like symptoms. These mice were implanted with Human Stem Cells and were able to walk again. While this isn't a cure, or even a treatment, what this DOES do is create a new area of research in MS.
Mice With 'MS-Like' Condition Walk After Stem Cell Treatment
Monday, May 19, 2014
Friday, August 12, 2011
Freshmedx completes Lung cancer diagnostic test clinical trial
Freshmedx, a private, Utah-based company focused on development, manufacturing, marketing and sales of non-invasive medical diagnostics for life-threatening disease, has completed its proprietary Computerized Bioconductance Test (CB Test) clinical trial.
Freshmedx said the CB Test is non-invasive, simple to perform, involves no ionizing radiation and differs from other lung cancer 'biomarkers' by focusing strictly upon characterization of a radiologically indeterminate lung mass.
In the trial, the CB Test demonstrated 90% sensitivity and 92% specificity in distinguishing between benign and malignant indeterminate masses confirmed by biopsy or stable disease.
The details of the Freshmedx sponsored clinical trial design and its results are expected to be presented at several conferences later this year, including the International Association for the Study of Lung Cancer World Conference on Lung Cancer and the European Respiratory Society Annual Congress.
Freshmedx also has partnering and distribution relationships in Mexico and China where the pre-biopsy evaluation of lung cancer may be limited to those with the resources and access to advanced technologies.
Freshmedx Clinical Affairs VP Karleen Callahan said the CB Test has the potential to be administered immediately upon discovery of an indeterminate finding by CT, and helps inform the physician whether an immediate biopsy is warranted or if longer term, radiological follow-up is appropriate.
Freshmedx said the CB Test is non-invasive, simple to perform, involves no ionizing radiation and differs from other lung cancer 'biomarkers' by focusing strictly upon characterization of a radiologically indeterminate lung mass.
In the trial, the CB Test demonstrated 90% sensitivity and 92% specificity in distinguishing between benign and malignant indeterminate masses confirmed by biopsy or stable disease.
The details of the Freshmedx sponsored clinical trial design and its results are expected to be presented at several conferences later this year, including the International Association for the Study of Lung Cancer World Conference on Lung Cancer and the European Respiratory Society Annual Congress.
Freshmedx also has partnering and distribution relationships in Mexico and China where the pre-biopsy evaluation of lung cancer may be limited to those with the resources and access to advanced technologies.
Freshmedx Clinical Affairs VP Karleen Callahan said the CB Test has the potential to be administered immediately upon discovery of an indeterminate finding by CT, and helps inform the physician whether an immediate biopsy is warranted or if longer term, radiological follow-up is appropriate.
Subscribe to:
Posts (Atom)